36288-93-4

Basic information

• Product Name: Benzamide, N-(2-aminoethyl)-2-hydroxy-
• CAS NO: 36288-93-4
• Molecular Formula: C9H12N2O2
• Molecular Weight: 180.206
• Mol File: 36288-93-4.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Benzamide, N-(2-aminoethyl)-2-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-(2-aminoethyl)-2-hydroxy-(36288-93-4)
• EPA Substance Registry System: Benzamide, N-(2-aminoethyl)-2-hydroxy-(36288-93-4)

Safety Data

• Hazardous Substances Data: 36288-93-4(Hazardous Substances Data)

Upstream product

• 118-55-8 phenyl Salicylate 
• 107-15-3 ethylenediamine 
• 61141-14-8 anionic phenyl salicylate 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 1204318-12-6 benzyl 2-(2-hydroxybenzamido)ethylcarbamate 
• 6345-72-8 N,N'-bis(2-hydroxybenzoyl)ethylenediamine 
• 119-36-8 methyl salicylate 
• 69-72-7 salicylic acid 

Downstream Products

• 1202748-58-0 (E)-N-(2-(3,5-dibromo-2-hydroxybenzylideneamino)ethyl)-2-hydroxybenzamide 
• 1202748-56-8 (E)-2-hydroxy-N-(2-(2-hydroxy-5-iodobenzylideneamino)ethyl)benzamide 
• 1202748-52-4 (E)-2-hydroxy-N-(2-(2-hydroxybenzylideneamino)ethyl)benzamide 
• 1202748-54-6 (E)-N-(2-(5-chloro-2-hydroxybenzylideneamino)ethyl)-2-hydroxybenzamide 
• 1202748-60-4 (E)-2-hydroxy-N-(2-((2-hydroxynaphthalen-1-yl)methyleneamino)ethyl)benzamide 
• 1204317-86-1 N-(2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido] ethyl)-2-hydroxybenzamide 
• 850034-01-4 N-[2-(2,2-dimethoxy-ethylamino)-ethyl]-2-hydroxy-benzamide 
• 219721-34-3 N-(2-hydroxybenzylidene)-N'-(2-hydroxybenzoyl)ethylenediamine 
• 1644598-99-1 N-{2-[(2-hydroxybenzoyl)amino]ethyl}-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide 
• 1261242-29-8 C₂₄H₁₉FN₆O₂S 
• 1350454-81-7 N-(2-(4-(6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)pyrimidin-2-ylamino)ethyl)-2-hydroxybenzamide 

Relevant articles and documents

Substituent-tuned structure and luminescence sensitizing towards Al3+ based on phenoxy bridged dinuclear EuIII complexes

To develop a LnIII complex-supported chemsensor, two new phenoxy bridged dinuclear EuIII complexes, [Eu2(H2L)3(NO3)3]·3CH3CN (EuL) and [Eu2(H2L′)2(NO3)4]·3CH3CN (EuL′), constructed by two new structurally related salicylamide salen-like ligands, 1-(2-hydroxy-benzamido)-2-(2-hydroxy-5-nitro-benzylideneamino)-ethane (H3L) and 1-(2-hydroxy-benzamido)-2-(2-hydroxy-4-diethylamino-benzylideneamino)-ethane (H3L′), have been synthesized and structural analysis shows that the different substitution groups on 2-(iminomethyl)phenol moiety have significant effects on their structures. Upon excitation of the ligand-centered absorption band at 375 nm, emissions both originating from ligands and EuIII ions were observed in the two EuIII compounds with the EuIII-centered emission intensity more than three times higher than that of ligand-centered emission. The capability of EuL and EuL′ for selective detection Al3+ ions were evaluated and the results indicate EuL exhibits a turn-on luminescent enhancement as high as 5.7 fold with Kd = 1.53 × 10-4 in CH3CN, but comparable compound EuL′ could not detect Al3+ among various cations. The considerably 'turn-on' luminescence response of EuL concomitantly led to the apparent color change from reddish to brilliant red, which could also be identified by naked eyes easily under UV lamp. This luminescence enhanced response can be explained in terms of the decrease of non-radiative transitions in EuL in addition to excited-state intra-molecular proton transfer (ESIPT) and photo-induced electron transfer suppression upon Al3+ coordination which is also rationalized by a theoretical calculation.

Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies

A series of imidazothiazole derivatives possessing potential activity against melanoma cells were investigated for molecular mechanism of action. The target compounds were tested against V600E-B-RAF and RAF1 kinases. Compound 1zb is the most potent agains

COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY

The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.